Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05742802 · ClinicalTrials.gov registry record · Phase 3
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,713
- Enrollment target
- 20
- Study locations
NCT05742802: Active Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
NCT05742802 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,713 participants, above the 604-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05742802, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,713 participants
- Enrollment target
- 20
- Study locations
Study Summary
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Primary Outcome
The primary efficacy endpoint is the rate of severe COPD exacerbations.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT Tozorakimab 1
- COMBINATION_PRODUCT Tozorakimab 2
Study Locations (20)
Florida
- Research Site - Boynton Beach
- Research Site - Cape Coral
- Research Site - Ormond Beach
- Research Site - Pensacola
- Research Site - Plantation
- Research Site - Tampa
- Research Site - Winter Park
California
- Research Site - Lincoln
- Research Site - Newport Beach
- Research Site - Northridge
Illinois
- Research Site - Evergreen Park
- Research Site - Normal
Louisiana
- Research Site - Baton Rouge
- Research Site - Zachary
Alabama
- Research Site - Sheffield
Arizona
- Research Site - Tempe
Indiana
- Research Site - Greenwood
Kansas
- Research Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,713 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2026-05-28 |
| Phase | Phase 3 |
What the registry record for NCT05742802 still lists
NCT05742802 is an interventional study that assigns participants to a tested intervention. Its 1,713 participants enrollment target places it among the larger protocols in the corpus, above the 604-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (184% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05742802 names 20 study sites across 10 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05742802 about?
NCT05742802 is a clinical study titled "Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).". Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
What is the current status of trial NCT05742802?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,713 participants. The study started on 2023-03-06. Estimated completion is 2026-05-28.
What conditions does trial NCT05742802 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT05742802?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Tozorakimab 1 (COMBINATION_PRODUCT), Tozorakimab 2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05742802?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05742802 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05742802's enrollment target sits among peer trials
1,713 3rd of 36 higher than 34 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI